- CEO
- Kartik Rajendran
- Full Time Employees
- 3,749
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Godrej BKC Mumbai MA India 400 051
- IPO Date
- Nov 3, 1994
- Business
- Abbott India Limited, a subsidiary of Abbott Laboratories headquartered in Mumbai and founded in 1944, operates as one of India's fastest-growing pharmaceutical companies, focusing on high-quality branded generic medicines across multiple therapeutic areas including women's health, gastroenterology, central nervous system, metabolics, multi-specialty, and vaccines; it offers over 125 products such as Thyronorm for hypothyroidism, Duphaston for miscarriage and IVF support, Duphalac and Cremaffin Plus for constipation, Digene antacids, Brufen analgesics, Vertin for vertigo, Udiliv for cholestatic liver disease, Influvac influenza vaccines, Zolfresh for insomnia, and recent launches like Linorma T3, Cremagel-L, and Brufen P; the company manufactures 20.1% of net sales at its Goa facility, supported by additional production in Baddi, Himachal Pradesh, and maintains a robust distribution network with over 8,100 stockists reaching rural and urban India as well as Nepal, Sri Lanka, Maldives, and Bhutan. In FY 2022-23, Abbott India reported revenue of Rs 5,349 crore, up 8.9%, with profit after tax rising 18.9% to Rs 949 crore and EBITDA at Rs 1,360 crore; it launched 10 new products including four first-to-market innovations across women's health, gastroenterology, metabolics, and multi-specialty, strengthening market leadership with top brands like Thyronorm and Udiliv ranking in India's top 15 pharmaceuticals. The company employs over 3,700 people, invests in R&D with 130 scientists addressing local needs, and advances digital health solutions, patient awareness campaigns such as Making India Thyroid Aware and Balance Awareness for vertigo, and public-private partnerships to upgrade 75 primary healthcare centers across nine states.